News
ATHE
--
0.00%
--
Alterity to present at the 7th International Congress of Multiple System Atrophy
and , /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format from .
PR Newswire - PRF · 02/26 12:45
Alterity Therapeutics reports 1H results
Alterity Therapeutics (ATHE): 1H GAAP EPS of -A$0.65.Revenue of A$1.93M (+3.2% Y/Y)Press Release
Seekingalpha · 02/25 23:21
Alterity surges on funding win for ATH434 development
Alterity Therapeutics shares jump ([[ATHE]] +18.7%) after it announces the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead
Seekingalpha · 02/09 15:35
Alterity Therapeutics Announces $495K In Funding From Michael J. Fox Foundation For ATH434 Dose Optimization For Parkinson's Disease Clinical Trials
NEW YORK, Feb. 9, 2021 /PRNewswire/ -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company") has today announced the award of a grant from The Michael J. Fox
Benzinga · 02/09 13:55
Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson's ...
PR Newswire · 02/09 13:53
Alterity Therapeutics names Dr. David Stamler as CEO
Alterity Therapeutics ([[ATHE]] +1.8%) announces the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately.Dr Stamler joined Alterity Therapeutics in June 2017 as Chief Medical
Seekingalpha · 01/07 15:49
Dr David Stamler Appointed CEO
, /PRNewswire/ -- The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointment of Dr to the role of Chief Executive Office effective immediately.
PR Newswire - PRF · 01/07 13:00
Dr David Stamler Appointed CEO
The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately.
PR Newswire · 01/07 13:00
Dr David Stamler Appointed CEO
The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately.
PR Newswire · 01/07 13:00
Dr David Stamler Appointed CEO
The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately.
PR Newswire · 01/07 13:00
Alterity and UniQuest partner to reverse bacterial resistance to antibiotics
Alterity Therapeutics (ATHE) announces it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland to novel zinc ionophore technology to combat antimicrobial resistance in superbugs."The approach
Seekingalpha · 12/21/2020 21:57
Alterity and UniQuest partner to reverse bacterial resistance to antibiotics
, /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the commercialisation company of The (UQ), to novel zinc ionophore technology to combat antimicr...
PR Newswire - PRF · 12/21/2020 21:42
Alterity and UniQuest partner to reverse bacterial resistance to antibiotics
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to combat ant...
PR Newswire · 12/21/2020 13:30
Alterity and UniQuest partner to reverse bacterial resistance to antibiotics
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to combat ant...
PR Newswire · 12/21/2020 13:30
Alterity and UniQuest partner to reverse bacterial resistance to antibiotics
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to combat ant...
PR Newswire · 12/21/2020 13:30
Is Alterity Therapeutics (ASX:ATH) In A Good Position To Deliver On Growth Plans?
Simply Wall St. · 12/09/2020 14:46
Is Alterity Therapeutics (ASX:ATH) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 12/09/2020 14:46
Is Alterity Therapeutics (ASX:ATH) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 12/09/2020 14:46
Zoom Video Communications, CureVac leads premarket losers' pack
Titan Pharmaceuticals (TTNP) -15%.Tuniu (TOUR) -15% on Q3 earnings release.Medigus (MDGS) -15% on appointment of new finance chief at MedigusECMOHO (MOHO) -14% on Q3 earnings release.Minerva Neurosciences (NERV) -14% after announcing outcome of Type C meeting with
Seekingalpha · 12/01/2020 13:47
The November Market Grinds Along
While it may not be my worst month this year, November may end up being the choppiest month for day trading I’ve traded so far in 2020.
Benzinga · 11/23/2020 17:19
Webull provides a variety of real-time ATHE stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ATHE
Alterity Therapeutics Limited, formerly Prana Biotechnology Limited, is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.